Key terms

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CYTK news

Mar 21 7:34am ET 5 Stocks Hedge Funds Love and have Analysts Support Mar 18 4:55am ET Cytokinetics to replace Calix in S&P 400 at open on 3/18 Mar 14 7:30am ET Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS) Mar 06 7:03am ET Cytokinetics price target lowered to $99 from $103 at Mizuho Mar 05 7:25am ET Truist Financial Gives a Buy Rating to Cytokinetics (CYTK) Mar 01 5:30pm ET Calix to replace Cytokinetics in S&P 600 at open on 3/18 Mar 01 5:28pm ET Cytokinetics to replace Calix in S&P 400 at open on 3/18 Mar 01 1:21am ET Optimistic Outlook on Cytokinetics: Buy Rating Affirmed Amid Anticipated Growth and Strategic Milestones Mar 01 12:56am ET Buy Rating Affirmed for Cytokinetics Amid Strong Clinical Progress and Strategic Commercial Preparations Feb 29 7:35am ET Cytokinetics joins initiative to recognize international rare disease day Feb 29 7:21am ET Truist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK) Feb 28 5:05pm ET Buy Rating Affirmed for Cytokinetics Amidst Strong Clinical Progress and Strategic Growth Initiatives Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today Feb 28 7:37am ET Cytokinetics, The Mended Hearts, Women Heart launch ENACT initiative Feb 28 7:30am ET Cytokinetics (CYTK) Gets a Buy from Piper Sandler Feb 28 6:25am ET Buy Rating Affirmed for Cytokinetics Amid Strong Financials and Positive Clinical Trials Feb 28 5:20am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (CYTK), Alphatec Holdings (ATEC) and Masimo (MASI) Feb 28 3:35am ET Barclays Remains a Buy on Cytokinetics (CYTK) Feb 28 2:25am ET Buy Rating Affirmed on Cytokinetics Amid Anticipated SEQUOIA-HCM Data and Promising Drug Developments Feb 28 1:00am ET Analysts’ Top Healthcare Picks: BioCryst (BCRX), Cytokinetics (CYTK) Feb 28 12:10am ET Analysts Are Bullish on These Healthcare Stocks: Athira Pharma (ATHA), BeiGene (BGNE) Feb 27 4:03pm ET Cytokinetics sees FY24 revenue $3M-$5M, consensus $28.54M Feb 27 4:02pm ET Cytokinetics reports Q4 EPS ($1.38), consensus (97c) Feb 27 7:20am ET Aficamten’s Market Potential and Competitive Analysis: A Balanced Outlook Amidst Uncertainties Feb 13 5:27am ET Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Alector (ALEC) and Cytokinetics (CYTK) Feb 13 5:19am ET Buy Rating Affirmed for Cytokinetics as Camzyos Prescriptions Rise and Confidence in Dosing Grows Feb 05 10:55pm ET Buy Rating Affirmed for Cytokinetics Amid Management Transition and Promising Clinical Milestones Feb 05 2:05pm ET Cytokinetics: A Strong Buy Amid Management Changes and Strategic Developments Feb 05 1:47pm ET Cytokinetics weakness a buying opportunity, says Truist Feb 05 4:20am ET Buy Rating for Cytokinetics: Growth Potential and Market Expansion Forecasted Amid Clinical Trials

No recent press releases are available for CYTK

CYTK Financials

1-year income & revenue

Key terms

CYTK Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CYTK Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms